Denali Therapeutics Inc. Gain (Loss) on Disposition of Assets
Denali Therapeutics Inc. (DNLI) reported Gain (Loss) on Disposition of Assets of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2026-02-26
- Denali Therapeutics Inc. gain (loss) on disposition of assets for the quarter ending 2025-12-31 was $0.00.
- Denali Therapeutics Inc. gain (loss) on disposition of assets for the quarter ending 2025-09-30 was $0.00.
- Denali Therapeutics Inc. gain (loss) on disposition of assets for the quarter ending 2025-06-30 was $0.00.
- Denali Therapeutics Inc. gain (loss) on disposition of assets for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Denali Therapeutics Inc. gain (loss) on disposition of assets for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Denali Therapeutics Inc. gain (loss) on disposition of assets for fiscal 2024 was $14.54M.
- Denali Therapeutics Inc. gain (loss) on disposition of assets for fiscal 2023 was $0.00.
- Denali Therapeutics Inc. gain (loss) on disposition of assets for fiscal 2022 was $0.00.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $14.54M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $14.54M 10-Q · filed 2025-11-06 | $14.54M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $14.54M 10-Q · filed 2025-08-11 | $14.54M derived: sum of 3 quarters · filed 2026-02-26 | $14.54M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $14.54M 10-Q · filed 2025-05-06 | $14.54M derived: sum of 2 quarters · filed 2026-02-26 | $14.54M derived: sum of 3 quarters · filed 2026-02-26 | $14.54M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $0.00 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |